Amsterdam, Netherlands (ots/PRNewswire) -
- Hospira Healthcare B.V. will also serve as regional headquarters
for Europe, Middle East and Africa --
Today Hospira, Inc. (pronounced Hos-PEER-ah), a global independent
specialty pharmaceutical and medication delivery company created in
April 2004 from the core global hospital products business of Abbott
Laboratories, announced that it has established its presence in
Europe with the launch of its Netherlands operation. As a result,
Abbott B.V. will transition its sales, marketing and distribution
activities regarding its hospital products portfolio, including
electronic pumps, infusion therapy, critical care products and
specialty injectable pharmaceuticals, to Hospira Healthcare B.V.
Hospira is dedicated to Advancing Wellness(TM): a pledge to develop,
manufacture and market products that help improve the safety and
efficacy of patient care.
Hospira Healthcare B.V. also serves as the company's regional
headquarters for Europe, Middle East and Africa (EMEA) and is
responsible for commercial operations, including sales and marketing;
customer service; human resources; finance; information technology;
and medical and regulatory support for countries within this
The launch of Hospira in the Netherlands is an important
advancement in the company's strategy to establish an independent
international infrastructure. In 2004, Hospira generated
approximately $2.6 billion (USD) in sales with approximately 15
percent coming from sales outside the United States. As Hospira
expands its international presence, the company will broaden its
offering of innovative technology solutions to the rest of the world.
As the international marketplace outside the United States is at
least as large as the size of the U.S. hospital market, Hospira is
well positioned for growth.
"Hospira has strong relationships with our hospital customers
developed over many years," said John Scott, regional director,
Hospira Healthcare B.V. "As an established leader in the hospital
market, Hospira is excited about our opportunities as an independent
company to advance wellness for our hospital customers and patients
in the EMEA region."
A Rich History, a Solid Outlook
Customer relationships are at the heart of Hospira's businesses
and provide a strong base for future growth. Hospira has
long-standing customer relationships worldwide that span "the
continuum of care" -- hospitals, alternate site clinics, home
healthcare providers and long-term care facilities.
"We expect that customers will embrace a company like Hospira that
is dedicated to the hospital and can offer new technologies and tools
that will enable doctors, hospital pharmacists and nurses to provide
the safest and highest-quality care for their patients in a
cost-effective manner," said Tjerk Balk, country manager,
Netherlands, Hospira Healthcare B.V.
A Leader in Patient and Healthcare Worker Safety
Globally, Hospira is a leader in developing and providing patient
and healthcare worker safety solutions. Improving patient safety is a
global problem. In fact, a number of countries have already initiated
patient safety plans and legislation to help address the issue.
Additionally, in 2004, the World Health Organization launched the
World Health Alliance for Patient Safety to coordinate a global
response to this growing concern.
Hospira is dedicated to enhancing patient and healthcare worker
safety through continued innovation in products, programs and
processes. For example, Hospira is at the forefront of eliminating
needles from its products to protect healthcare workers against
needlestick injuries and blood exposure, resulting in improved
workplace safety. Hospira also completed one of the largest bar
coding efforts in the industry, encompassing more than 1,000 hospital
injectable pharmaceuticals and I.V. solutions -- a major step toward
reducing medication errors and improving patient safety. Globally,
bar coding pharmaceuticals has been discussed as one way to minimize
medication errors by ensuring that the right drug in the right dose
gets to the right patient in the right way at the right time.
Hospira is also committed to advancing patient safety through the
continued development of medication management systems and software
that can reduce the potential for medication errors, a worldwide
challenge for all healthcare providers. Hospitals have been focusing
increased attention and resources on how to prevent these errors.
Hospira's infusion devices and software can provide a way for
customers to help reduce the likelihood of medication errors during
the administration phase of I.V. therapy.
Hospira Healthcare B.V. will work with its customers and other
interested groups in the region to identify and evaluate the
suitability of products that can help address the recognised issues
of medication errors and patient and healthcare worker safety within
Hospira, Inc. is a global specialty pharmaceutical and medication
delivery company dedicated to Advancing Wellness(TM) by developing,
manufacturing and marketing products that help improve the
productivity, safety and efficacy of patient care. Created from the
core global hospital products business of Abbott Laboratories in
April 2004, Hospira is a new company with 70 years of service to the
hospital industry. The company's portfolio includes: one of the
industry's broadest lines of generic acute-care injectables, which
help address the high cost of proprietary pharmaceuticals in
hospitals; integrated solutions for medication management and
infusion therapy; and the leading U.S. injectable contract
manufacturing business. Headquartered in Lake Forest, Ill., United
States, north of Chicago, Hospira has approximately 13,000 employees
and 14 manufacturing facilities worldwide. For news and other
information, visit www.hospira.nl or www.hospira.com.
@@start.t1@@ Private Securities Litigation Reform Act of 1995 -- A Caution
Concerning Forward-Looking Statements@@end@@
Some statements in this news release may be forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995. Hospira cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual results
to differ materially from those indicated in the forward-looking
statements. Economic, competitive, governmental, technological and
other factors that may affect Hospira's operations and may cause
actual results to be materially different from expectations include
the risks and uncertainties set forth under the heading "Item 1
Business -- Risk Factors" in Hospira's Annual Report on Form 10-K for
the year ended Dec. 31, 2004, filed with the Securities and Exchange
Commission, which are incorporated by reference. Hospira undertakes
no obligation to release publicly any revisions to forward-looking
statements as the result of subsequent events or developments.
Web site: http://www.hospira.com
ots Originaltext: Hospira, Inc.
Im Internet recherchierbar: http://www.presseportal.ch
Media, John Scott of Hospira Healthcare B.V., +31-23-5560100,
Rosalinde van de Wall of Fleishman-Hillard, +31-20-4065930/Photo:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO, AP
Archive: http://photoarchive.ap.org, PRN Photo Desk,